Slidesets

Share

Program Content

Activities

  • BTKi for Frontline CLL/SLL
    Therapy Selection for CLL/SLL in the Frontline Setting
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 09, 2022

    Expires: December 08, 2023

    View Activity
  • BTKi for R/R CLL/SLL
    Treatment of Relapsed/Refractory CLL/SLL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 09, 2022

    Expires: December 08, 2023

    View Activity
  • BTKi for MCL
    Overview of Treatment for Mantle Cell Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 09, 2022

    Expires: December 08, 2023

    View Activity
  • BTKi Overview
    Review of Current and Emerging BTK Inhibitors
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 09, 2022

    Expires: December 08, 2023

    View Activity
  • <i>EP</i>: BTKi for CLL and B-Cell Malignancies
    ExpressPoints:
    Breakthrough Therapeutics for CLL and Other B-Cell Malignancies: Focus on BTK Inhibitors From Development to Clinical Integration
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2022

    Expires: December 15, 2023

    View Activity

Faculty

cover img faculity

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

cover img faculity

Jeff DONOTUSESharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

cover img faculity

Ian W. Flinn, MD, PhD

Chief Scientific Officer
One Oncology and Tennessee Oncology
Nashville, Tennesse

cover img faculity

Susan M. O Brien, MD

Professor of Medicine
Department of Leukemia
University of Texas M.D. Anderson Cancer Center
Houston, Texas

Provided by

ProCE Banner

Supporters

BeiGene Ltd

Lilly